Penumbra Inc (PEN) Q3 2016 10-Q Quarterly Earnings

Short answer

Penumbra Inc (PEN) filed its Q3 2016 10-Q quarterly report on Nov 3, 2016 for the quarter ended Sep 30, 2016.

AI summary of MD&A and risk factor updates

Revenue $67.2M, up 33.3% YoY from $50.4M
Operating margin negative 2.0% vs 4.3% YoY; gross margin 63.8% vs 66.4%
Best segment Peripheral Vascular: $19.7M, up 39.3%; Neuro: $47.5M, up 30.9%
Cash $15.9M vs $19.5M at December 31, 2015; operating cash used $10.1M
Outlook: liquidity sufficient for at least 12 months; headwinds from product launches, hiring costs and geographic mix

Product liability: Montgomery complaint over Penumbra Coil 400, potential $35 million damages exceeding insurance coverage
Regulatory risk: medical device excise tax suspension ends after two years commencing January 1, 2016
Competitive risk: large, well-capitalized rivals pressure physician adoption and product-market share
Operational risk: new product launches require advance inventory and personnel investment, risking write-downs
Liquidity risk: operating activities consumed $10.1 million, with $15.9 million cash and $126.0 million investments

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Compare quarters, check guidance or see what insiders and funds did around the report.